For hereditary cancers, the approved PARPi indications for breast, ovarian, pancreatic, and prostate malignancies rely on the fact that, in these tumor types, the germline BRCA1/2 alteration is almost always accompanied by somatic second-hit inactivation of the remaining allele. The gene discussed is BRCA1; the disease is neoplasm.